ArticlePsychopharmacology2026
What goes up must comedown: prevalence rates, characteristics, and coping strategies concerning MDMA aftereffects.
Article in Psychopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
rationaleMDMA is increasingly being studied for therapeutic applications, yet the prevalence and characteristics of post-acute negative effects remain debated.
objectivesWe aimed to characterize MDMA's post-acute negative effects, including prevalence and symptom profile among recreational users. Given preclinical work and limited human evidence suggesting that certain supplements and antidepressants may mitigate MDMA's negative effects, we also assessed the use of these substances as coping strategies.
methodsWe conducted a cross-sectional online survey of 497 MDMA-experienced participants recruited from Prolific. The survey assessed post-acute negative effects prevalence, timing, and duration; post-acute side effects; emotional changes, suicidal ideation; and intentional use of supplements or antidepressants to manage symptoms. We compared characteristics of post-acute side effects between MDMA users who self-reported ever experiencing a negative post-acute MDMA experience (colloquially known as a 'comedown') and those who did not.
results74.5% of participants reported experiencing a period of post-acute negative effects at least once, with onset occurring approximately 24 hours post-ingestion and lasting an average of 40 hours. The most common symptoms were fatigue (88.1%), difficulty concentrating (85.7%), restlessness (82.9%), and headache (79.7%). 14.6% of post-acute negative effects experiencers endorsed passive suicidal ideation and 6.2% endorsed active suicidal ideation. Regarding coping strategies, 30.3% reported using supplements (most commonly N-acetyl-cysteine, acetyl-L-carnitine, and magnesium) and 5.1% reported using antidepressants, with moderate perceived helpfulness.
conclusionsPost-acute negative effects of MDMA appear prevalent among recreational users in a cross-sectional sample, characterized by fatigue, negative affect, and elevated suicidal ideation. These findings highlight post-acute risks that warrant further investigation.
Indexed as
Identifiers
42891831What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.